Tardive Dyskinesia Clinical Case Review

Christoph U. Correll, MD, professor of psychiatry at The Zucker School of Medicine at Hofstra/Northwell and professor and chair of the department of child and adolescent psychiatry at Charité University Medicine in Berlin, Germany, discusses the selected treatment for the first case.

Editor’s note: The following is an automatically generated transcript of the above video.

"Which treatment is selected for Paul and with Paul in a shared decision making model? Since Paul has a history of non-adherence to treatment in the past, simplicity of titration and dosing is desired. So in this case, the addition of valbenazine to the ongoing paliperidone palmitate 150 milligrams once a month is discussed and agreed upon because you can start it on one dose and only have one titration step to the best working dose.

So you start with valbenazine 40 milligrams a day, get some mild sedation for the first two weeks, which then dissipated thereafter. And at the next office visit one month later, since this is not a trial and we wanna see how he's doing, we could have increased it at week one, but why not wait for a month? There is some improvement of the tardive dyskinesia movements, but the improvement is insufficient, so valbenazine is increased to the best dose in the clinical trials and that is 80 milligrams, and he actually didn't have any newly emerging side effects that he notices."